Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term hepatic function of patients with compensated cirrhosis following successful direct-acting antiviral treatment for hepatitis C virus infection.
Ogawa E, Kawano A, Ooho A, Furusyo N, Satoh T, Takahashi K, Kajiwara E, Dohmen K, Nakamuta M, Azuma K, Koyanagi T, Yamashita N, Yanagita K, Ichiki Y, Kuniyoshi M, Yamashita N, Morita C, Sugimoto R, Kato M, Shimoda S, Nomura H, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Ogawa E, et al. Among authors: ooho a. J Gastroenterol Hepatol. 2022 Feb;37(2):371-377. doi: 10.1111/jgh.15703. Epub 2021 Oct 24. J Gastroenterol Hepatol. 2022. PMID: 34618379
Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney disease.
Ogawa E, Furusyo N, Azuma K, Nakamuta M, Nomura H, Dohmen K, Satoh T, Kawano A, Koyanagi T, Ooho A, Takahashi K, Kato M, Shimoda S, Kajiwara E, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Ogawa E, et al. Among authors: ooho a. Antiviral Res. 2018 Nov;159:143-152. doi: 10.1016/j.antiviral.2018.10.003. Epub 2018 Oct 6. Antiviral Res. 2018. PMID: 30300717
Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: Results from a multicenter, real-world cohort study.
Ogawa E, Furusyo N, Nakamuta M, Nomura H, Satoh T, Takahashi K, Koyanagi T, Kajiwara E, Dohmen K, Kawano A, Ooho A, Azuma K, Kato M, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Ogawa E, et al. Among authors: ooho a. Hepatol Res. 2019 Jun;49(6):617-626. doi: 10.1111/hepr.13328. Epub 2019 Apr 9. Hepatol Res. 2019. PMID: 30849206
Ledipasvir and sofosbuvir for 12 weeks for hepatitis C virus genotype 2 infection: A propensity score matched analysis.
Ogawa E, Nomura H, Nakamuta M, Kawano A, Dohmen K, Kajiwara E, Satoh T, Koyanagi T, Takahashi K, Ooho A, Azuma K, Furusyo N, Kato M, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Ogawa E, et al. Among authors: ooho a. Hepatol Res. 2020 Feb;50(2):174-181. doi: 10.1111/hepr.13437. Epub 2019 Nov 19. Hepatol Res. 2020. PMID: 31634412
Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Ogawa E, Nomura H, Nakamuta M, Furusyo N, Koyanagi T, Dohmen K, Ooho A, Satoh T, Kawano A, Kajiwara E, Takahashi K, Azuma K, Kato M, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Ogawa E, et al. Among authors: ooho a. Liver Int. 2020 Jul;40(7):1578-1589. doi: 10.1111/liv.14482. Epub 2020 Apr 30. Liver Int. 2020. PMID: 32304611
Development of Hepatocellular Carcinoma in Patients Aged 75-84 Years With Chronic Hepatitis C Treated With Direct-Acting Antivirals.
Ogawa E, Nomura H, Nakamuta M, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Ooho A, Azuma K, Takahashi K, Satoh T, Koyanagi T, Ichiki Y, Kuniyoshi M, Yanagita K, Amagase H, Morita C, Sugimoto R, Kato M, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Ogawa E, et al. Among authors: ooho a. J Infect Dis. 2022 Aug 26;226(3):431-440. doi: 10.1093/infdis/jiaa359. J Infect Dis. 2022. PMID: 32584386 Free PMC article.
Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C.
Ogawa E, Nomura H, Nakamuta M, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Ooho A, Azuma K, Takahashi K, Satoh T, Koyanagi T, Ichiki Y, Kuniyoshi M, Yanagita K, Amagase H, Morita C, Sugimoto R, Kato M, Shimoda S, Hayashi J. Ogawa E, et al. Among authors: ooho a. Cancers (Basel). 2020 Sep 11;12(9):2602. doi: 10.3390/cancers12092602. Cancers (Basel). 2020. PMID: 32933027 Free PMC article.
HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort.
Tanaka Y, Ogawa E, Huang CF, Toyoda H, Jun DW, Tseng CH, Hsu YC, Enomoto M, Takahashi H, Furusyo N, Yeh ML, Iio E, Yasuda S, Lam CP, Lee DH, Haga H, Yoon EL, Ahn SB, Wong G, Nakamuta M, Nomura H, Tsai PC, Jung JH, Song DS, Dang H, Maeda M, Henry L, Cheung R, Yuen MF, Ueno Y, Eguchi Y, Tamori A, Yu ML, Hayashi J, Nguyen MH; REAL-C Investigators. Tanaka Y, et al. Hepatol Int. 2020 Dec;14(6):1023-1033. doi: 10.1007/s12072-020-10105-2. Epub 2020 Dec 4. Hepatol Int. 2020. PMID: 33277685
Long-term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct-acting antivirals.
Ogawa E, Nakamuta M, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Ooho A, Azuma K, Takahashi K, Satoh T, Koyanagi T, Yamashita N, Ichiki Y, Yamashita N, Kuniyoshi M, Yanagita K, Amagase H, Morita C, Sugimoto R, Kato M, Shimoda S, Nomura H, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Ogawa E, et al. Among authors: ooho a. J Gastroenterol Hepatol. 2022 Jan;37(1):190-199. doi: 10.1111/jgh.15659. Epub 2021 Aug 23. J Gastroenterol Hepatol. 2022. PMID: 34374128 Free PMC article.
15 results